EyeGene Inc.

EyeGene Inc.
Stock Exchange Korea Exchange
EPS
KRW856
Market Cap
KRW261.64 B
Shares Outstanding
10.99 M
Public Float
9.41 M

Profile

Address
Unit 910, Gangseo Han-gang Zai B
Seoul SL 07528
Korea, Republic Of
Employees -
Website http://www.eyegene.co.kr
Updated 09/14/2018
Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.

Financials

View All

Won-Il Yoo
Chief Executive Officer & Director
Yang-Je Cho
Chief Technology Officer & Director